LLY

1,076.96

+0.06%↑

JNJ

207.49

-0.14%↓

ABBV

230.16

+0.01%↑

UNH

331.59

+1.17%↑

AZN

92.89

+0.42%↑

LLY

1,076.96

+0.06%↑

JNJ

207.49

-0.14%↓

ABBV

230.16

+0.01%↑

UNH

331.59

+1.17%↑

AZN

92.89

+0.42%↑

LLY

1,076.96

+0.06%↑

JNJ

207.49

-0.14%↓

ABBV

230.16

+0.01%↑

UNH

331.59

+1.17%↑

AZN

92.89

+0.42%↑

LLY

1,076.96

+0.06%↑

JNJ

207.49

-0.14%↓

ABBV

230.16

+0.01%↑

UNH

331.59

+1.17%↑

AZN

92.89

+0.42%↑

LLY

1,076.96

+0.06%↑

JNJ

207.49

-0.14%↓

ABBV

230.16

+0.01%↑

UNH

331.59

+1.17%↑

AZN

92.89

+0.42%↑

Search

Certara Inc

Atidarymo kaina

SektoriusSveikatos priežiūra

8.77 -1.24

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

8.61

Max

8.74

Pagrindiniai rodikliai

By Trading Economics

Pajamos

3.5M

1.5M

Pardavimai

46K

105M

P/E

Sektoriaus vid.

130.143

78.892

Pelnas, tenkantis vienai akcijai

0.14

Pelno marža

1.458

Darbuotojai

1,487

EBITDA

-6.5M

23M

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+41.28% upside

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-428M

1.5B

Ankstesnė atidarymo kaina

10.01

Ankstesnė uždarymo kaina

8.77

Naujienos nuotaikos

By Acuity

94%

6%

359 / 374 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bearish Evidence

Certara Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-12-24 21:41; UTC

Įsigijimai, susijungimai, perėmimai

Nvidia to Buy Chip-Designer Groq for $20 Billion, CNBC Reports

2025-12-28 23:57; UTC

Uždarbis

'Avatar: Fire and Ash' Tops Domestic Box Office Again -- Barrons.com

2025-12-28 23:48; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-12-28 23:48; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2025-12-28 23:48; UTC

Rinkos pokalbiai

Nikkei May Rise on Weaker Yen -- Market Talk

2025-12-28 10:30; UTC

Įsigijimai, susijungimai, perėmimai

There's No Happy Ending for Movie Theaters, No Matter Who Wins Warner -- Heard on the Street -- WSJ

2025-12-26 20:22; UTC

Rinkos pokalbiai

Oil Loses Ground On Russia-Ukraine Peace Efforts -- Market Talk

2025-12-26 20:13; UTC

Rinkos pokalbiai

U.S. Natural Gas Gains on Colder Weather Outlook -- Market Talk

2025-12-26 19:24; UTC

Įsigijimai, susijungimai, perėmimai

Nvidia's Groq Deal Is an Instagram Moment -- With 1 Big Risk -- Barrons.com

2025-12-26 17:45; UTC

Rinkos pokalbiai

U.S. Diesel Down on Lower Crude Prices, Freight-Sector Lull -- Market Talk

2025-12-26 15:52; UTC

Rinkos pokalbiai

Oil Futures Turn Lower After Steady Start -- Market Talk

2025-12-26 14:58; UTC

Rinkos pokalbiai

Silver, Gold Reach New Highs Amid Geopolitical Tension -- Market Talk

2025-12-26 14:41; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Look to End Week Higher -- Market Talk

2025-12-26 14:28; UTC

Rinkos pokalbiai

Dollar Indexes Flat as Yen Rally Wanes -- Market Talk

2025-12-26 13:47; UTC

Rinkos pokalbiai

Oil Futures Steady in Thin Holiday Trade -- Market Talk

2025-12-26 07:22; UTC

Rinkos pokalbiai

Comex Gold Futures' Strong Bullish Momentum in Play, Chart Shows -- Market Talk

2025-12-26 05:03; UTC

Rinkos pokalbiai

Malaysian Ringgit Likely to Face Pressure From Dollar Strength in 1Q -- Market Talk

2025-12-26 03:38; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2025-12-26 03:38; UTC

Rinkos pokalbiai

Korean Won Strengthens, Supported by Verbal Interventions -- Market Talk

2025-12-26 02:44; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-12-26 02:44; UTC

Rinkos pokalbiai

Singapore Dollar Weakens Slightly on Likely Position Adjustments -- Market Talk

2025-12-26 01:39; UTC

Rinkos pokalbiai

China's Central Bank Signals Possibility of Easing Policy in Coming Months -- Market Talk

2025-12-26 01:14; UTC

Rinkos pokalbiai

Oil Edges Higher Amid Geopolitical Tensions -- Market Talk

2025-12-26 00:34; UTC

Rinkos pokalbiai

Yen Mostly Weakens Amid Risk-on Sentiment -- Market Talk

2025-12-26 00:15; UTC

Rinkos pokalbiai

Nikkei Gains 0.6%, Led by Tech, Videogame Stocks -- Market Talk

2025-12-25 23:42; UTC

Rinkos pokalbiai

Nikkei May Trade in Range; Yen in Focus -- Market Talk

2025-12-25 23:40; UTC

Rinkos pokalbiai

Gold Edges Higher Amid Geopolitical Risks -- Market Talk

2025-12-25 00:20; UTC

Įsigijimai, susijungimai, perėmimai

Nike Climb Boosts Dow, S&P 500 -- 2nd Update

2025-12-24 22:22; UTC

Įsigijimai, susijungimai, perėmimai

Nvidia, Groq Strike AI Tech Licensing Deal -- Barrons.com

2025-12-24 21:26; UTC

Įsigijimai, susijungimai, perėmimai

Nvidia to Buy Chip-Designer Groq for $20B, CNBC Reports

Akcijų palyginimas

Kainos pokytis

Certara Inc Prognozė

Kainos tikslas

By TipRanks

41.28% į viršų

12 mėnesių prognozė

Vidutinis 12.56 USD  41.28%

Aukščiausias 16 USD

Žemiausias 9 USD

Remiantis 11 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Certara Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

11 ratings

6

Pirkti

5

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

11.27 / 12.79Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Very Strong Bearish Evidence

Vidutinės trukmės periodas

Very Strong Bullish Evidence

Ilgalaikis periodas

Strong Bullish Evidence

Rinkos nuotaikos

By Acuity

359 / 374 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Labai stiprus meškų rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Vidutinis

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Certara Inc

Certara, Inc., together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics. The company provides Simcyp Simulator, a mechanistic biosimulation platform mechanistic biosimulation investigational new drug and translational stages; Simcyp Biopharmaceutics, used to identify and refine drug formulations; and Simcyp Secondary Intelligence which integrates toxicology with quantitative analysis of networks of molecular and functional biological changes to identify drug toxicity and adverse drug reactions. In addition, it offers Phoenix WinNonlin, a platform for non-compartmental analysis, pharmacokinetic/pharmacodynamic, and toxicokinetic; phoenix hosted, that provides a secured and validated certara amazon web services workspace; Phoenix NLME, a population modeling and simulation software for nonlinear mixed effects models; and pirana modeling workbench. Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange, used to define data standards and specifications; and Metadata Repository, to enable study design using controlled and standardized data. It serves life sciences companies, biopharmaceutical companies, research organizations, academic institutions, and global regulators, as well as animal health, crop science, bio science, medical devices, and public sector industries. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.
help-icon Live chat